Moderna, Inc. (MRNA)
| Market Cap | 9.78B |
| Revenue (ttm) | 3.08B |
| Net Income (ttm) | -2.90B |
| Shares Out | 389.08M |
| EPS (ttm) | -7.53 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,040,237 |
| Open | 24.66 |
| Previous Close | 24.28 |
| Day's Range | 24.61 - 25.48 |
| 52-Week Range | 23.15 - 79.96 |
| Beta | 1.93 |
| Analysts | Hold |
| Price Target | 43.50 (+73.03%) |
| Earnings Date | Nov 6, 2025 |
About MRNA
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for MRNA stock is "Hold." The 12-month stock price target is $43.5, which is an increase of 73.03% from the latest price.
News
Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism
CAMBRIDGE, MA / ACCESS Newswire / September 2, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that five abstracts on its investigational mRNA therapeutics have been accepted for presentation at th...
IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies
RESEARCH TRIANGLE PARK, N.C. and CAMBRIDGE, Mass.
mRNA Biotechs - Long-Term Value Risks Abound
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c...
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2
CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applica...
Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna announced today that Health Canada has autho...
Moderna to Present at Upcoming Conferences in September 2025
CAMBRIDGE, MA / ACCESS Newswire / August 21, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced its participation in the following upcoming investor conferences: Morgan Stanley's 23rd Annual Global He...
FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply
Pfizer Inc.'s PFE COVID-19 vaccine for children under five may lose U.S. Food and Drug Administration authorization this fall, raising the possibility of supply shortages and prompting Moderna Inc. MR...
Moderna's stock takes a hit as RFK Jr. backs out of some mRNA vaccine deals
Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the biotechnology company's vaccines and said it would cancel some contracts and stop fundi...
Moderna Q2 Earnings Review: Downsizing Triggers Selloff, But I'm Long-Term Bullish
Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) net loss. MRNA stock has plummeted over 70% in the past year, reflecting in...
Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
Moderna, Inc. (MRNA) Q2 2025 Earnings Call Transcript
Moderna, Inc. (NASDAQ:MRNA) Q2 2025 Earnings Conference Call August 1, 2025 8:00 AM ET Company Participants James M. Mock - Chief Financial Officer Lavina Talukdar - Senior VP & Head of Investor Rela...
Moderna Stock Drops as Firm Cuts Revenue Outlook on UK Vaccine Deliveries Delay
Shares of Moderna (MRNA) fell sharply Friday after the company lowered the top end of its full-year revenue outlook because of a delay in vaccine deliveries to the UK.
Moderna cuts 2025 revenue to $2.2B after UK booster delay
Moderna has lowered the high end of its 2025 revenue forecast, citing a delay in Covid vaccine shipments to the UK. The company now expects between $1.5 billion and $2.2 billion in revenue, down $300 ...
Moderna is laying off 10% of its workforce. Does RFK Jr. have anything to do with it?
Biotech giant Moderna announced it will lay off 10% of its workforce in a move CEO Stéphane Bancel called “a difficult decision but necessary step forward,” in an internal memo sent to employees on Ju...
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
Moderna Stock Drops After Earnings Report. What Has Wall Street Worried.
Moderna stock was falling in Friday's premarket after the drugmaker's better-than-expected quarterly results were overshadowed by a cut to the high end of its full-year outlook.
Moderna quarterly sales beat Street estimates on COVID booster sales, cost cuts
Moderna topped Wall Street sales expectations and reported a lower-than-expected second-quarter loss on Friday, driven by robust Spring COVID booster demand and aggressive cost cuts.
Moderna cuts high end of 2025 revenue outlook on vaccine shipment delay in U.K.
Moderna lowered the high end of its 2025 revenue outlook, citing a delay in vaccine shipments to the U.K. The company lost less than Wall Street analysts were expecting for the second quarter and pos...
Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates
Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 projected revenue range to $1.5 to $2.2 billion, reflecting a $300 million reducti...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
UK Court of Appeal Confirms Moderna's EP'949 Patent is Valid and Infringed by Pfizer/BioNTech
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna's EP'949 patent. This decision affirms the...
Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
Moderna Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Moderna, Inc. MRNA will release earnings results for the second quarter, after the closing bell on Friday, Aug. 1.
More than 800 Moderna employees will lose their jobs this year as costs are slashed
In a note to employees on Thursday, Moderna Inc. said it was laying off about 10% of its global workforce as part of the biotechnology company's plan to cut costs by $1.5 billion over the next couple ...